| CytoMed Therapeutics [GDTC] - Last Close: $3.49 CytoMed has been on a tear as of late. Last Thursday, the biotech firm was granted a U.S. patent for its licensed CAR-gamma Delta T Cell Technology. Since the news broke, shares have been marching steadily higher, and GDTC is seeing more big gains in today's premarket. GDTC is up 169.0% in today's premarket on elevated trading volume, despite no new announcements from the company. My Take: I don't think this patent totally explains this sudden move in GDTC, but I don't have anything else to go on at the moment. This firm is based in Singapore, so it's possible there was some international news that's slipping under U.S. investors' radar at the moment. Better Therapeutics [BTTX] - Last Close: $0.90 A new regulatory green light is boosting shares of Better Therapeutics.
After Monday's close, the MedTech firm said the FDA authorized its AspyreRx digital therapeutic for adult patients with Type 2 diabetes.
Better Therapeutics said it expects to launch the product commercially in Q4 in light of the FDA's decision. News of the approval sparked sent shares of BTTX soaring in Monday's after-market, and the stock is currently showing a 35.5% gain on elevated volume. My Take: BTTX fell 19.6% on Monday, so this news came at a good time for the company. It appears to have strong support at $0.63 per share, so there could be upside ahead if it can keep the momentum rolling. Adial Pharma [ADIL] - Last Close: $0.2023 Adial Pharma investors are enjoying a much-needed rebound rally. The company's shares are rallying after Nasdaq granted its request to extend the deadline to file its quarterly report until Aug. 21st, 2023. Adial Pharma will be expected to publish financial results for the quarter ended June 30th by the deadline to avoid penalties. The company also expects the quarterly report to include a plan to regain compliance with Nasdaq's minimum shareholder equity rules. ADIL is up 23.5% on the news. My Take: ADIL looks like it's in bad shape. There could be more opportunities for short-term pops in share prices in the weeks ahead, but I am bearish. Crown Electrokinetics [CRKN] - Last Close: $0.102 Crown Electrokinetics is making big waves in today's premarket.
The high-tech materials firm published a Form 424B4 on Monday relating to an upcoming offering from certain selling shareholders.
Shares CRKN fell 13.5% on Monday following the report's release, but the stock is rebounding in today's premarket. CRKN is up 27.3% ahead of today's open, and it's the premarket's most actively traded stock. My Take: CRKN's sudden reversal could be a sign that the stock is approaching its bottom. GainersTrinity Place [TPHS] >> +10.9%Acumen Pharma [ABOS] >> +22.7%Akanda [AKAN] >> +9.1%Wavedancer [WAVD] >> +12.9%DeclinersViridian Therapeutics [VRDN] >> (18.8%) VOXX [VOXX] >> (14.1%)DSS [DSS] >> (16.8%)Iovance Biotherapeutics [IOVA] >> (10.9%) None None | 